Immuno Vaccine Inc (IMMVF) 0.5930 $IMMVF
Immunovaccine to Present at 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:02AM CST
Immunovaccine Inc. ("Immunovaccine"
(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will present a corporate update at the 17th Annual BIO CEO & Investor Conference. The conference will take place February 9-10, 2015 at the Waldorf Astoria New York hotel.
IMV.TO: 0.69 (+0.02)
Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines
Marketwired - Wed Jan 28, 6:03AM CST
Immunovaccine Inc. ("Immunovaccine" (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that three different recombinant protective antigen (rPA) vaccines formulated with its novel DepoVax(TM) enhancement technology protected animals against a lethal anthrax challenge after a single vaccination. The National Institutes of Health (NIH) led study demonstrates the potential of DepoVax as a universal enabler of single dose rPA-based anthrax vaccines.
IMV.TO: 0.69 (+0.02)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine
Marketwired - Tue Jan 20, 6:02AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that it has received clearance from Health Canada to conduct a Phase I clinical study of its respiratory syncytial virus (RSV) vaccine in healthy adults. The RSV vaccine is formulated in Immunovaccine's proprietary DepoVax(TM) adjuvanting platform and is initially being developed to protect the elderly population from infection. In preclinical studies, the DepoVax-based vaccine demonstrated the ability to protect animals against RSV, a potentially severe respiratory virus that predominantly affects the elderly and infants. Immunovaccine plans to initiate the Phase I trial in the first half of 2015, with initial data expected later this year.
IMV.TO: 0.69 (+0.02)
Immunovaccine to Present at 7th Annual Biotech Showcase Conference
Marketwired - Wed Jan 07, 6:01AM CST
Immunovaccine Inc. ("Immunovaccine" (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will present a corporate update at the 7th Annual Biotech Showcase Conference. The conference will take place January 12-14, 2015 at the Parc 55 Wyndham San Francisco Union Square Hotel.
IMV.VN: 0.730 (+0.010), IMV.TO: 0.69 (+0.02)
Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer
Marketwired - Wed Dec 10, 6:01AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that DPX-Survivac, the Company's lead cancer vaccine candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. Ovarian cancer patients who have no measurable disease following their initial standard surgery and chemotherapy treatments have an unmet need that may be served by the DPX-Survivac therapy. DPX-Survivac is designed to activate T cells of the immune system that are expected to recognize and eliminate cancer cells in an attempt to keep patients in remission longer.
IMV.TO: 0.69 (+0.02)
Immunovaccine Receives Final Approval to Graduate to TSX
Marketwired - Mon Nov 24, 4:24PM CST
Immunovaccine Inc. ("Immunovaccine" or the "Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced it has received final approval from Toronto Stock Exchange ("TSX" to graduate from TSX Venture Exchange and list its common shares (the "Common Shares" on TSX.
IMV.VN: 0.730 (+0.010)
Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of DPX-Survivac in Recurrent Lymphoma
Marketwired - Wed Nov 19, 4:11PM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that it has received clearance from Health Canada to conduct a Phase II clinical study of DPX-Survivac in patients with diffuse large B cell lymphoma (DLBCL). The Company-sponsored trial will evaluate DPX-Survivac, Immunovaccine's lead cancer vaccine candidate, in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL.
IMV.VN: 0.730 (+0.010)
Immunovaccine Announces Financial Results for Quarter Ended September 30, 2014
Marketwired - Fri Nov 14, 3:40PM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended September 30, 2014.
IMV.VN: 0.730 (+0.010)
Immunovaccine Receives Conditional Approval to Graduate to Toronto Stock Exchange (TSX)
Marketwired - Wed Nov 12, 7:07AM CST
Immunovaccine Inc. ("Immunovaccine" or the "Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced it has received conditional approval from Toronto Stock Exchange ("TSX" to graduate from TSX Venture Exchange and list its common shares (the "Common Shares" on TSX.
IMV.VN: 0.730 (+0.010)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 25.34 (+1.20), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), ADMP: 6.50 (-0.01), GNCA: 8.93 (-0.07)
Immunovaccine to Present at 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:02AM CST
Immunovaccine Inc. ("Immunovaccine"
(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will present a corporate update at the 17th Annual BIO CEO & Investor Conference. The conference will take place February 9-10, 2015 at the Waldorf Astoria New York hotel. IMV.TO: 0.69 (+0.02)
Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines
Marketwired - Wed Jan 28, 6:03AM CST
Immunovaccine Inc. ("Immunovaccine"
(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that three different recombinant protective antigen (rPA) vaccines formulated with its novel DepoVax(TM) enhancement technology protected animals against a lethal anthrax challenge after a single vaccination. The National Institutes of Health (NIH) led study demonstrates the potential of DepoVax as a universal enabler of single dose rPA-based anthrax vaccines. IMV.TO: 0.69 (+0.02)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine
Marketwired - Tue Jan 20, 6:02AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that it has received clearance from Health Canada to conduct a Phase I clinical study of its respiratory syncytial virus (RSV) vaccine in healthy adults. The RSV vaccine is formulated in Immunovaccine's proprietary DepoVax(TM) adjuvanting platform and is initially being developed to protect the elderly population from infection. In preclinical studies, the DepoVax-based vaccine demonstrated the ability to protect animals against RSV, a potentially severe respiratory virus that predominantly affects the elderly and infants. Immunovaccine plans to initiate the Phase I trial in the first half of 2015, with initial data expected later this year. IMV.TO: 0.69 (+0.02)
Immunovaccine to Present at 7th Annual Biotech Showcase Conference
Marketwired - Wed Jan 07, 6:01AM CST
Immunovaccine Inc. ("Immunovaccine"
(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will present a corporate update at the 7th Annual Biotech Showcase Conference. The conference will take place January 12-14, 2015 at the Parc 55 Wyndham San Francisco Union Square Hotel. IMV.VN: 0.730 (+0.010), IMV.TO: 0.69 (+0.02)
Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer
Marketwired - Wed Dec 10, 6:01AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that DPX-Survivac, the Company's lead cancer vaccine candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. Ovarian cancer patients who have no measurable disease following their initial standard surgery and chemotherapy treatments have an unmet need that may be served by the DPX-Survivac therapy. DPX-Survivac is designed to activate T cells of the immune system that are expected to recognize and eliminate cancer cells in an attempt to keep patients in remission longer. IMV.TO: 0.69 (+0.02)
Immunovaccine Receives Final Approval to Graduate to TSX
Marketwired - Mon Nov 24, 4:24PM CST
Immunovaccine Inc. ("Immunovaccine" or the "Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced it has received final approval from Toronto Stock Exchange ("TSX" to graduate from TSX Venture Exchange and list its common shares (the "Common Shares" on TSX. IMV.VN: 0.730 (+0.010)
Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of DPX-Survivac in Recurrent Lymphoma
Marketwired - Wed Nov 19, 4:11PM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that it has received clearance from Health Canada to conduct a Phase II clinical study of DPX-Survivac in patients with diffuse large B cell lymphoma (DLBCL). The Company-sponsored trial will evaluate DPX-Survivac, Immunovaccine's lead cancer vaccine candidate, in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. IMV.VN: 0.730 (+0.010)
Immunovaccine Announces Financial Results for Quarter Ended September 30, 2014
Marketwired - Fri Nov 14, 3:40PM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended September 30, 2014. IMV.VN: 0.730 (+0.010)
Immunovaccine Receives Conditional Approval to Graduate to Toronto Stock Exchange (TSX)
Marketwired - Wed Nov 12, 7:07AM CST
Immunovaccine Inc. ("Immunovaccine" or the "Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced it has received conditional approval from Toronto Stock Exchange ("TSX" to graduate from TSX Venture Exchange and list its common shares (the "Common Shares" on TSX. IMV.VN: 0.730 (+0.010)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 25.34 (+1.20), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), ADMP: 6.50 (-0.01), GNCA: 8.93 (-0.07)
